Exclusive Summary

• - Approved uses cover both first- and second-line metastatic pancreatic cancer with strong guideline endorsement and clear demand.
• - Originator launched in 2015–2016; no approved generics in US/EU so far, with complex liposomal CMC barriers creating a near-term window.
• - API meets JP/BP/USP/EP, enabling multi-region dossier alignment and faster registrations.
• - High originator pricing allows a 30–50% discount strategy to drive uptake in price-sensitive markets.
• - Partnering with specialty oncology distributors to push guideline-driven regimens (NALIRIFOX and 5-FU/LV combo) can accelerate volume.